| [1] |
Pascale A,Pais R,Ratziu V,et al.An overview of nonalcoholic steatohepatitis:past,present and future directions[J].J Gastrointestin Liver Dis,2010,19(4):415-423.
|
| [2] |
Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].J Gastroenterol Hepatol,2013,28(Suppl 1):11-17.
|
| [3] |
Feldstein AE,Charatcharoenwitthaya P,Treeprasertsuk S,et al.The natural history of non-alcoholic fatty liver disease in children:a follow-up study for up to 20 years[J].Gut,2009,58(11):1538-1544.
|
| [4] |
Wattacheril J,Issa D,Sanyal A,et al.Nonalcoholic steatohepatitis(NASH)and hepatic fibrosis:emerging therapies[J].Annu Rev Pharmacol Toxicol,2018,58(1):649-662.
|
| [5] |
Fabbrini E,Sullivan S,Klein S,et al.Obesity and nonalcoholic fatty liver disease:biochemical,metabolic,and clinical implications[J].Hepatology,2010,51(2):679-689.
|
| [6] |
Medes G,Thomas A,Weinhouse S,et al.Metabolism of neoplastia tissue.IV.A study of lipid synthesis in neoplastia tissue slices in vitro[J].Cancer Res,1953,13(1):27-29.
|
| [7] |
Currie E,Schulze A,Zechner R,et al.Cellular fatty acid metabolism and cancer[J].Cell Metab,2013,18(2):153-161.
|
| [8] |
Mounier C,Bouraoui L,Rassart E,et al.Lipogenesis in cancer progression[J].Int J Oncol,2014,45(2):485-492.
|
| [9] |
Kim J,DeBerardinis RJ.Blocking fatty acid synthesis reduces lung tumor growth in mice[J].Nature Medicine,2016,22(10):1077-1078.
|
| [10] |
Martinez UE,Peiris M,Pestell RG,et al.Cancer metabolism:a therapeutic perspective[J].Nat Rev Clin Oncol,2017,14(1):11-31.
|
| [11] |
Samuel VT,Shulman GI.Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases[J].Cell Metab,2018,27(1):22-41.
|
| [12] |
Francis P.Kuhajda M.Fatty-acid synthase and human cancer:new perspectives on its role in tumor biology[J].Nutrition,2000,16(3):202-208.
|
| [13] |
Blank HM,Maitra M,Polymenis M,et al.Lipid biosynthesis:when the cell cycle meets protein synthesis[J].Cell Cycle,2017,16(10):905-906.
|
| [14] |
Yu LP,Kim YS,Tong L,et al.Mechanism for the inhibition of the carboxyltransferase domain of acetyl-coenzyme A carboxylase by pinoxaden[J].Proc Natl Acad Sci U S A,2010,107(51):22072-22077.
|
| [15] |
Zhang H,Tweel B,Tong L,et al.Molecular basis for the inhibition of the carboxyltransferase domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop[J].Proc Natl Acad Sci U S A,2004,101(16):5910-5915.
|
| [16] |
Zhang H,Yang Z,Shen Y,et al.Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase[J].Science,2003,299(5615):2064-2067.
|
| [17] |
Corbett JW,Freeman-Cook KD,Elliott R,et al.Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2[J].Bioorg Med Chem Lett,2010,20(7):2383-2388.
|
| [18] |
Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery[J].Cell Mol Life Sci,2005,62(16):1784-1803.
|
| [19] |
Tong L,Harwood HJ Jr.Acetyl-coenzyme A carboxylases:versatile targets for drug discovery[J].J Cell Biochem,2006,99(6):1476-1488.
|
| [20] |
Fullerton MD,Galic S,Marcinko K,et al.Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin[J].Nat Med,2013,19(12):1649-1654.
|
| [21] |
Bengtsson C,Blaho S,Saitton DB,et al.Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats[J].Bioorg Med Chem,2011,19(10):3039-3053.
|
| [22] |
Mcgarry JD,Leatherman GF,Foster DW,et al.Carnitine palmitoyltransferase 1.the site of inhibition of hepatic fatty acid oxidation by malonyl-CoA[J].J Biol Chem,1978,253(12):4128-4136.
|
| [23] |
Cho YS,Lee JI,Shin D,et al.Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK[J].Biochem Biophys Res Commun,2010,391(1):187-192.
|
| [24] |
Harwood HJ.Treating the metabolic syndrome:acetyl-CoA carboxylase inhibition[J].Expert Opin 2005,9(2):267-281.
|
| [25] |
Shen Y, Volrath SL, Weatherly SC, et al. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A,a macrocyclic polyketide natural product[J].Mol Cell,2004,16(6):881-891.
|
| [26] |
Harwood HJ Jr.,Petras SF,Shelly LD,et al.Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations,inhibit fatty acid synthesis,and increase fatty acid oxidation in cultured cells and in experimental animals[J].J Biol Chem,2003,278(39):37099-37111.
|
| [27] |
Zhang H,Tweel B,Li J,et al.Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186[J].Structure,2004,12(9):1683-1691.
|
| [28] |
Griffith DA,Kung DW,Esler WP,et al.Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes[J].J Med Chem,2014,57(24):10512-10526.
|
| [29] |
Kim CW, Addy C, Kusunoki J, et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans:a bedside to bench investigation[J].Cell Metab,2017,26(2):394-406.
|
| [30] |
Abel R,Mondal S,Masse C,et al.Accelerating drug discovery through tight integration of expert molecular design and predictive scoring[J].Curr Opin Struct Biol,2017,43:38-44.
|
| [31] |
Harriman G,Greenwood J,Bhat S,et al.Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis,improves insulin sensitivity,and modulates dyslipidemia in rats[J].PNAS,2016,113(13):E1976-E1805.
|
| [32] |
Svensson RU,Parker SJ,Eichner LJ,et al.Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models[J].Nat Med,2016,22(10):1108-1119.
|
| [33] |
Lally JSV,Ghoshal S,DePeralta DK,et al.Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma[J].Cell Metab,2018,29(1):1-9.
|
| [34] |
Ratner M.Gilead bets big on Nimbus′ fatty liver disease drug[J].Nat Biotechnol,2016,34(6):575-576.
|
| [35] |
Stiede K,Miao W,Blanchette HS,et al.Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects:a randomized,double-blind,crossover study[J].Hepatology,2017,66(2):324-334.
|
| [36] |
Loomba R,Kayali Z,Noureddin M,et al.GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease[J].Gastroenterology,2018,155(5):1463-1473.
|
| [37] |
Petrova E,Scholz A,Paul J,et al.Acetyl-CoA carboxylase inhibitors attenuate WNT and Hedgehog signaling and suppress pancreatic tumor growth[J].Oncotarget,2017,8(30):48660-48670.
|
| [38] |
Yamashita T,Kamata M,Endo S,et al.Design,synthesis,and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors[J].Bioorg Med Chem Lett,2011,21(21):6314-6318.
|
| [39] |
Kamata M,Yamashita T,Kina A,et al.Design,synthesis,and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors[J].Bioorg Med Chem Lett,2012,22(11):3643-3647.
|
| [40] |
Kamata M,Yamashita T,Kina A,et al.Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors[J].Bioorg Med Chem Lett,2012,22(14):4769-4772.
|
| [41] |
Mizojiri R,Asano M,Tomita D,et al.Discovery of novel selective acetyl-CoA carboxylase(ACC)1 inhibitors[J].J Med Chem,2018,61(3):1098-1117.
|
| [42] |
Chonan T,Tanaka H,Yamamoto D,et al.Design and synthesis of disubstituted(4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors[J].Bioorg Med Chem Lett,2010,20(13):3965-3968.
|
| [43] |
Chonan T,Wakasugi D,Yamamoto D,et al.Discovery of novel(4-piperidinyl)-piperazines as potent and orally active acetyl-CoA carboxylase 1/2 non-selective inhibitors:F-Boc and triF-Boc groups are acid-stable bioisosteres for the Boc group[J].Bioorg Med Chem,2011,19(5):1580-1593.
|
| [44] |
Keil S,Muller M,Zoller G,et al.Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation[J].J Med Chem,2010,53(24):8679-8687.
|
| [45] |
Lovering F,Bikker J,Humblet C,et al..Escape from flatland:increasing saturation as an approach to improving clinical success[J].J Med Chem,2009,52(21):6752-6756.
|
| [46] |
Bourbeau MP,Siegmund A,Allen JG,et al.Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase[J].J Med Chem,2013,56(24):10132-10141.
|
| [47] |
Nishiura Y, Matsumura A, Kobayashi N, et al. Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy[J].Bioorg Med Chem Lett,2018,28(14):2498-2503.
|
| [48] |
Jasmina M,Dominika C,Caroline P,et al.Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity[J].PNAS,2010,107(20):9093-9098.
|
| [49] |
Jump DB,Torres-Gonzalez M,Olson LK,et al.Soraphen A,an inhibitor of acetyl CoA carboxylase activity,interferes with fatty acid elongation[J].Biochem Pharmacol,2011,81(5):649-660.
|
百度学术
下载:
